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Nitric oxide produces HLA-G nitration and induces
metalloprotease-dependent shedding creating a tolerogenic milieu
Introduction
Nitric oxide (NO) is a very reactive free radical produced
from L-arginine by the enzyme nitric oxide synthase
(NOS) – reviewed in [1]. There are three isoforms of this
enzyme: two of these, neuronal (nNOS) and endothelial
(eNOS), are expressed constitutively and are collectively
termed constitutive (cNOS), producing NO in the
nanomolar range; and a third form, inducible (iNOS),
produces NO in the micromolar range. NO is a versatile
signalling mediator2,3 that interacts with different mole-
cules regulating almost every critical cellular function.1 In
addition, NO reacts with superoxide anions producing
the powerful oxidant peroxynitrite. Peroxynitrite and the
NO-derived nitrite can react with tyrosine to produce
nitrotyrosine,4 which can change protein function.
Inducible NOS can be induced in the immune cells,
mainly in macrophages, modulating the type and exten-
sion of the immune response.1,5 For example, NO inter-
feres with the signalling of the interleukin-2 (IL-2)
receptor,6 decreases the tumour necrosis factor-a receptor
expression,7 and selectively induces apoptosis in T helper
type 1 lymphocytes.8
Human leucocyte antigen G (HLA-G) is an immuno-
suppressive molecule with a low degree of polymor-
phism9and a limited tissue distribution, mainly restricted
to trophoblasts.10 However, it can be expressed ectopically
by antigen-presenting cells11,12 and tumour cells.13 There
are four membrane-bound isoforms (HLA-G1, -G2, -G3
and -G4) and three soluble isoforms (HLA-G5, -G6 and
-G7) generated by alternative splicing of a primary tran-
script.14,15 HLA-G binds at least three surface receptors,
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Summary
Human leucocyte antigen G (HLA-G) is a tolerogenic molecule that pro-
tects the fetus from maternal immune attack, may favour tumoral
immunoescape and is up-regulated in viral and inflammatory diseases.
The aim of this work was to discover if nitric oxide (NO) could affect
HLA-G expression or function because NO is an important modulator of
innate and adaptive immunity. For this purpose HLA-G expression and
function were analysed following treatment with a NO donor or a peroxy-
nitrite donor in various cell lines expressing HLA-G either spontaneously
or upon transfection. Results showed NO-dependent nitration of both cel-
lular and soluble HLA-G protein, but not all HLA-G moieties underwent
nitration. Endogenous biosynthesis of NO by both U-937-HLA-G1 and
M8-HLA-G5 stable transfectants also caused HLA-G nitration. The NO
decreased total HLA-G cellular protein content and expression on the cell
surface, while increasing HLA-G shedding into the culture medium. This
effect was post-transcriptional and the result of metalloprotease activity.
By contrast, NO pretreatment did not affect HLA-G capability to suppress
NK cytotoxicity and lymphocyte proliferation. Our studies show that NO
regulates the availability of HLA-G molecules without modifying their
biological activities.
Keywords: human leucocyte antigen-G; immunosuppression; monocytes;
nitration; nitric oxide
Abbreviations: DETA-NO, N-(4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]butyl) propane-1,3-diamine; SIN-1,
3-[morpholinosydnonimine hydrochloride].
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ILT2 (CD85j), ILT4 (CD85d) and KIR2DL4 (CD158d),16
inhibiting the cytotoxicity of natural killer (NK) and anti-
gen-specific CD8+ cells,17 the allogeneic proliferation of
CD4+ cells,18 and promoting a shift toward a type T
helper type 2 cytokine profile.19 HLA-G1 can be shed from
cellular membrane by metalloproteases,20,21 and this solu-
ble form (sHLA-G1) retains the tolerogenic properties.22
Both NOS23 and HLA-G are expressed in the placenta.
In several diseases, such as coeliac disease, multiple sclero-
sis and HIV infection, HLA-G24–27 and iNOS28–30 expres-
sion gives rise both to an increase in circulating HLA-G
and to protein nitration. It has been shown that NO can
influence the function of some tolerogenic molecules such
as the enzyme indoleamine 2,3-dioxygenase.31 There are
no data related to the effect of NO on HLA-G. The aim
of this work was to know if high NO output could affect
HLA-G expression or function. In this work we show that
NO to some extent nitrates the HLA-G protein and
increases proteolytic shedding of HLA-G, which maintains
its suppressive properties in soluble form.
Materials and methods
Cell line and cultures
The monocytic cell line U-937, the melanoma cell line
M8, the lymphoblastoid cell line LCL and the natural
killer cell line NKL were grown in RPMI-1640 medium
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, 100 lg/ml streptomycin and 2 mM L-glutamine
(Gibco, Carlsbad, CA). The transfected cells U-937-HLA-
G1 and M8-HLA-G5 were obtained as previously
described.32 The choriocarcinoma cell line JEG-3 was cul-
tured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, 100 U/ml
penicillin, 100 lg/ml streptomycin (Gibco). Cells were
cultured at 37 in a 5% CO2 humidified atmosphere.
The NO donors were N-(4-[1-(3-aminopropyl)-
2-hydroxy-2-nitrosohydrazino]butyl)propane-1,3-diamine
(DETA-NO; Alexis Corporation, La¨ufelfingen, Switzer-
land); and 3-[morpholinosydnonimine hydrochloride]
(SIN-1, Alexis Chemicals, San Diego, CA). The broad-
spectrum matrix metalloprotease inhibitor GM6001, its
negative control, NC-GM6001, and the specific inhibitors
of matrix metalloproteases 2/9 (INH 2/9), 3 (INH 3), and
8 (INH 8) were from Calbiochem (Darmstadt, Germany).
Cellular viability measured by trypan blue exclusion
was higher than 95% throughout the study.
Nitrotyrosine immunoprecipitation
Cells were lysed in nonidet P40 05% in Tris–HCl buffer
with protease inhibitors (Roche Applied Sciences,
Upstate, NY) and incubated with anti-nitrotyrosine anti-
body at a dilution of 1 : 230 for 30 min.31 Preincubation
of anti-nitrotyrosine antibody with nitrotyrosine 1 mM
for 1 hr was used as a control of immune specificity.
Immunoprecipitation was performed with an assay kit
purchased from Pierce Biotechnology Inc. (Rockford, IL)
according to the manufacturer’s instructions.
Western blotting
Protein concentration was quantified by the Bradford
assay (BioRad Laboratories, Hercules, CA) using bovine
serum albumin as standard. After centrifugation, 20 lg
total protein were denatured at 100 for 5 min in a pro-
tein sample buffer containing 125 mM Tris–HCl (pH 68),
4% sodium dodecyl sulphate (SDS), 30% glycerol, 5%
b-mercaptoethanol and 04% bromophenol. Proteins were
subjected to 10% polyacrylamide gel electrophoresis
under denaturing conditions, with subsequent electro-
blotting transfer onto a nitrocellulose membrane. The
membrane was blocked with 05% bovine serum albumin
in phosphate-buffered saline (PBS)–Tween 01% for 1 hr
at room temperature, and then incubated for 2 hr with
MEM-G/1 anti-HLA-G antibody (Abcam, Cambridge,
UK) diluted 1 : 2000 in PBS–Tween, or with anti-b-actin
(Abcam), diluted 1 : 5000 in PBS–Tween. Immunoblot
analysis was performed using a horseradish peroxidase-
conjugated anti-mouse antibody (1 : 5000; Amersham
Biosciences, Uppsala, Sweden), and developed using the
enhanced chemiluminescence kit (Amersham
Biosciences). For incubation with additional antibodies,
the membranes were previously stripped for 30 min at
56 in 625 mM Tris (pH 68), 2% SDS and 100 mM
b-mercaptoethanol.
Flow cytometry
Cells were incubated for 30 min at 4 in PBS containing
20% human serum (Sigma-Aldrich, St Louis, MO), and
stained with fluorescein isothiocyanate-conjugated anti-
HLA-G antibody MEM-G/9 (Exbio, Prague, Czech
Republic) for 20 min at 4. After washing, cells were fixed
in paraformaldehyde 1%. Control aliquots were stained
with the isotype-matched mouse antibody (Beckman
Coulter, Fullerton, CA). Fluorescence was detected by an
EPICS XL flow cytometer (Beckman Coulter).
Real time reverse transcription–polymerase chain
reaction analysis
Total RNA was extracted from three to five million cells
using an RNAeasy kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s recommendations. Residual
DNA was eliminated by DNase I treatment (10–20 units/
100 lg, Roche Applied Science, Basel, Switzerland) for
1 hr at 25. Reverse transcription was carried out using a
High-Capacity cDNA Archive Kit according to the
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manufacturer’s instructions (Applied Biosystems, Foster
City, CA). Real-time reverse transcription–polymerase
chain reaction (RT-PCR) was used to quantify variations
in the amounts of HLA-G transcripts after cell treatment
using the TaqMan Gene Expression Assay (Applied Bio-
system). GAPDH was used as the internal standard.
Enzyme-linked immunosorbent assay
Specific enzyme-linked immunosorbent assay (ELISA) for
HLA-G5 plus sHLA-G1 used anti-HLA-G MEM-G/9
(Exbio) as the capture antibody and anti-b2-microglobu-
lin (DAKO, Glostrup, Denmark) as the secondary anti-
body as described previously.12,33 Results were normalized
to the absorbance obtained from the control medium
without treatment.
Cytotoxic assay
Cells from the M8 cell line transfected and non-transfected
for HLA-G1 were incubated in the presence or absence of
1 mM DETA-NO. After 24 hr at 37, cells were washed
twice and incubated for 1 hr at 37 with 51Cr. After two
washes with complete RPMI-1640 medium, M8 cells were
cocultured with NKL cells for 4 hr at 37. The NKL cells
had been previously stimulated with IL-2 (100 U/ml) for
24 hr. Coculture was performed in duplicates and in several
M8 : NKL ratios: from 1 : 1 to 1 : 50. Then, 50 ll of each
supernatant was mixed with scintillation buffer
(Perkin Elmer, Waltham, MA) in a 96-well plate and then
read in a b-radiation counter (Wallac 1450; Amersham
Biosciences). Specific lysis level was calculated as the 51Cr-
release percentage from the maximum release:
% specific lysis ¼ 100
 ½ðsample c:p:m:  spontaneous releaseÞ
=ðmaximum release  spontaneous releaseÞ
The spontaneous release was the counts per min (c.p.m.)
measured in 51Cr-labelled M8 cells cultured in medium
without NKL cells. The maximum release was achieved
when 51Cr-labelled M8 cells were incubated with Triton-
X-100.
Proliferation assay
Mixed lymphocyte reaction (MLR) was performed in trip-
licate, between peripheral blood mononuclear cells
(PBMC) as responder cells and cells from the LCL cell line
as stimulatory cells. As a third part of this MLR, beads
(Ademtech, Pessac, France) were added with or without
HLA-G5 attached. The linkage between HLA-G5 and the
beads was through two types of anti HLA-G monoclonal
antibodies: anti-HLA-G5 5A6G7 (Exbio) and anti-HLA-G
6A10.34 The beads containing HLA-G5 were incubated
overnight at 4 in the presence or absence of DETA-NO
1 mM. LCL cells were irradiated with 75 Gy and the ratio
of culture was one LCL cell to two PBMC. Beads were
added in a ratio of 5000 beads per PBMC. After 5 days of
culture, 1 lCi [3H]thymidine (Amersham Biosciences)
was added to each well. After another 18 hr of culture,
cells were collected in a filter, scintillation buffer (Perkin
Elmer) was added and the filter was read in a b-radiation
counter (Wallac 1450, Amersham Biosciences).
Stimulatory assay
U-937 and U-937-HLA-G1 transfected cells
(500 000 cells/ml) were maintained for 2 days in com-
plete medium. Supernatants were then incubated for
24 hr in the presence or absence of DETA-NO 1 mM at
37. Then, T lymphocytes from healthy volunteers were
incubated for 5 hr in those supernatants. After washing, T
cells were stimulated with IL-2 2000 U/ml (Sigma-
Aldrich) and anti-CD3 027 lg/ml (Beckman Coulter)
and cultured for 4 days. Then the proliferation level of
lymphocytes was checked with a bromodeoxyuridine-
based colorimetric assay (Roche Molecular Biochemicals,
Mannheim Germany).
Statistical analysis
Data were expressed as mean ± standard deviation. For
statistical analysis the SPSS statistical program for Windows
(SPSS Inc., Chicago, IL) was used. Results were compared
with the Kruskal–Wallis and Mann–Whitney U non-para-
metric tests, and P < 005 was considered significant.
Results
NO can modify HLA-G protein by tyrosine nitration
Analysing the HLA-G sequence and structure, there are sev-
eral tyrosine residues susceptible to nitration.35 To address
this issue, we initially studied the HLA-G+ chorio-
carcinoma cell line JEG-3,10 which was treated with the per-
oxynitrite donor SIN-1 or the pure NO donor DETA-NO
for 24 hr, followed by immunoprecipitation of the cell
extract with anti-nitrotyrosine antibody. Western blot
using the anti-HLA-G antibody MEM-G/1 showed that
either SIN-1 or DETA-NO produced HLA-G nitration
(Fig. 1a). U-937 cells and M8-HLA-G5 cells produced NO
that nitrated endogenous proteins (ref. 31 and supplemen-
tary data), and interestingly, there was a band of nitrated
HLA-G1 and HLA-G5 in the lanes corresponding to cell
lysates from U-937-HLA-G1 and M8-HLA-G5 untreated
cells, respectively (Fig. 1a). Similarly, culture media from
U-937-HLA-G1 and M8-HLA-G5 were also immunopre-
cipitated with anti-nitrotyrosine antibody, and in the Wes-
tern blot there was a band corresponding to nitrated, shed
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HLA-G1 and HLA-G5 (Fig. 1b). These data were con-
firmed using the NO scavenger haemoglobin, which
impairs shed HLA-G1 nitration (Fig. 1b). These results
demonstrated that both exogenous and endogenous NO
produce HLA-G nitration, which can be detected both in
the cell and in the culture medium.
NO decreases HLA-G1 levels at the cell surface
Interestingly, the HLA-G cell surface expression decreased
after NO treatment. This observation was confirmed by
flow cytometric analysis in U937-HLA-G1 transfected cells
(Fig. 2a), where treatment with DETA-NO 10 lM for 24 hr
produced a significant decrease of HLA-G cell surface
expression (median fluorescence intensity of control,
10 ± 16; median fluorescence intensity after DETA-NO
10 lM, 45 ± 11; P < 005), and this reduction was more
as the concentration of DETA-NO increased. However,
haemoglobin as a NO scavenger blocked the DETA-NO-
mediated decrease in HLA-G1 expression. In addition,
treatment with SIN-1 for 24 hr decreased HLA-G1 cell sur-
face expression in U-937-HLA-G1-transfected cells (mean
fluorescence intensity control: 54 ± 08; mean fluorescence
intensity after SIN-1 10 lM: 38 ± 07; P < 005) (Fig. 2b).
These results demonstrated that NO and peroxynitrite
down-regulated HLA-G cell surface expression.
HLA-G remains in its native state in the presence of
NO
To find out whether this previous observation was the
result of an alteration in the HLA-G protein, we analysed
the HLA-G binding capacity to MEM-G/9, an antibody
which only attaches to HLA-G in its native form.36 We
treated culture medium containing sHLA-G1 with
increased concentrations of SIN-1 for 12 hr at 37, and
then we measured HLA-G concentrations in the medium
by ELISA using MEM-G/9 as the capture antibody. We
observed a significant (P < 005), apparently lower con-
centration of HLA-G1 in the medium treated with SIN-1
at concentrations in the millimolar range (Fig. 3). At NO
concentration lower than 1 mM, therefore, HLA-G pre-
dominates in its native form. In addition, the 10 lM and
1000 lM SIN-1-treated HLA-G1 supernatants were
immunoprecipitated with anti-nitrotyrosine antibody, and
ELISA of the non-nitrated HLA-G1 showed that
85 ± 19% and 65 ± 24% of the initial HLA-G1 did not
undergo nitration, respectively. We did not use higher
concentrations of SIN-1 because of its pro-apoptotic
effect in the millimolar range.31 We can conclude that
part of HLA-G protein remains unnitrated and in the
native form at NO concentrations below millimolar.
The decrease in HLA-G cell surface expression
produced by NO is a post-transcriptional effect
To address the mechanism involved in the NO-mediated
change of HLA-G cell surface expression, we initially
investigated whether it took place at the level of HLA-G
gene expression or was a post-transcriptional effect. For
this purpose, JEG-3 cells were treated with DETA-NO for
24 hr. Immunoblot analysis using the anti-HLA-G anti-
body MEM-G/1 showed a dose-dependent reduction in
the HLA-G total cellular content (Fig. 4a). However,
when HLA-G messenger RNA was evaluated by real-time
RT-PCR, we observed that DETA-NO did not change the
transcriptional levels significantly (Fig. 4b). We can
conclude that the NO-dependent change in HLA-G cell
surface expression is a post-transcriptional effect.
NO decreases HLA-G cell surface expression
employing metalloprotease-mediated shedding
To determine if this decrease of HLA-G cell surface levels
produced by NO was the result of HLA-G shedding to
39 000 HLA-GJEG-3 
(a) 
(b) 
Un
tre
at
ed
 
D
ET
A-
N
O
 
SI
N-
1 
Co
nt
ro
l (–
) 
Co
nt
ro
l (+
)
M8-HLA-G5 U-937-HLA-G1 
Co
nt
ro
l (+
) 
Un
tre
at
ed
 
Co
nt
ro
l (–
) 
Co
nt
ro
l (+
) 
Co
nt
ro
l (–
)  
Un
tre
at
ed
 
39 000 HLA-G
39 000 HLA-GU-937-HLA-G1 
Co
nt
ro
l (+
) 
Co
nt
ro
l (–
)  
Un
tre
at
ed
 
D
ET
A-
N
O
 
D
ET
A-
N
O
+
 h
ae
m
og
lo
bi
n
M8-HLA-G5 39 000 HLA-G
Figure 1. (a) Top panel: immunoblot analysis of human leucocyte
antigen G (HLA-G) nitration in JEG-3 treated with DETA-NO
100 lm or with SIN-1 100 lm for 24 hr. Bottom panel: immunoblot
analysis of HLA-G nitration in U-937-HLA-G1 and M8-HLAG5
cells. Positive control corresponds to a JEG-3 cellular lysate (top), or
U-937-HLA-G1 cellular lysate (bottom). (b) Immunoblot analysis of
HLA-G nitration in U-937-HLA-G1 and M8-HLA-G5 culture med-
ium. Cells were treated with DETA-NO 100 lm or DETA-NO plus
haemoglobin. Control (+) corresponds to a cell lysate of U-937-
HLA-G1 cells. Cell lysates and culture media were immunoprecipi-
tated using anti-3-nitrotyrosine antibody. Negative control was
preincubation of antibody with 3-nitrotyrosine 1 mm. Immunopre-
cipitated proteins were separated on sodium dodecyl sulphate–poly-
acrylamide gel, blotted onto a nitrocellulose membrane, and then
probed with anti-HLA-G MEM-G/1 antibody. A representative
experiment out of three is shown.
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the medium, we measured the concentration of HLA-G
in the conditioned medium by ELISA after 24 hr of NO
donor treatment. Figure 5(a) shows that DETA-NO pro-
duced a significant increase of HLA-G1 shedding from
the U937-HLA-G1 cells. The addition of haemoglobin at
a concentration of 20 lM impaired this HLA-G shedding
to the medium. Similarly to the effect caused by DETA-
NO, SIN-1 10 lM significantly increased HLA-G1 shed-
ding to the medium (P < 005) (Fig. 5a).
Metalloproteases are involved in HLA-G1 shedding,20,21
and to study if the effect of NO in HLA-G1 cell surface
expression and shedding was mediated by matrix metallo-
proteases, we treated U-937-HLA-G1 cells with DETA-
NO for 12 hr in the presence of matrix metalloproteases
inhibitors (Fig. 5b). Flow cytometry analysis showed that
the presence of GM6001, a broad-spectrum inhibitor of
metalloproteases, significantly increased HLA-G1 cell
surface expression (mean fluorescence intensity in
untreated cells: 44 ± 03; mean fluorescence in GM6001-
treated cells: 57 ± 03; P < 005), and diminished the
negative effect of DETA-NO in HLA-G1 cell surface
expression (mean fluorescence intensity in DETA-NO-
treated cells: 34 ± 01; mean fluorescence intensity in
DETA-NO plus GM6001-treated cells: 40 ± 01). Fur-
thermore, GM6001 decreased HLA-G1 shedding to the
medium (P < 005 related to untreated cells), and blocked
the release of HLA-G induced by DETA-NO (P < 005
related to cells treated with DETA-NO alone). The
GM6001 negative control, NC-GM6001, did not have any
effect on HLA-G1 cell surface expression (mean fluores-
cence intensity in NC-GM6001-treated cells: 46 ± 02)
and HLA-G shedding to the medium (Fig. 5b). However,
not all metalloproteases participate in HLA-G shedding:
while the inhibitors of metalloproteases 3 and 8 decreased
0 0·1 100 1000 
DETA-NO (µM) (a) 
+ Haemoglobin 20 µM
Mem -G/9-FITC 
10 1 
SIN-1 (µM)(b) 
0 10 
Figure 2. (a) Effect of DETA-NO on human leucocyte antigen G (HLA-G) cell surface expression in U-937-HLA-G1 cells for 24 hr in the
absence (top) or presence (bottom) of haemoglobin 20 lm. (b) Effect of SIN-1 on HLA-G surface expression in U-937-HLA-G1 cells for 24 hr.
Cells were stained with the anti-HLA-G antibody MEM-G/9-FITC and analysed by flow cytometry. Grey histograms represent control cells and
open histograms represent cells treated with DETA-NO or SIN-1, respectively. Dotted peaks represent irrelevant isotypic antibody. Data are
representative of three different experiments.
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HLA-G1 shedding either in the absence or in the presence
of DETA-NO, the inhibitor of metalloproteases 2 and 9
(INH 2/9) blocked neither HLA-G1 release to the med-
ium (Fig. 5b) nor the decrease in cell surface expression
(data not shown).
These results show that the effect of NO in HLA-G cell
surface expression is through metalloprotease-mediated
shedding to the medium.
HLA-G maintains its function under the presence of
nitric oxide
We have previously demonstrated that M8-HLA-G-trans-
fected cells, which express iNOS, can generate suppres-
sion,33 and here we have shown that the presence of NO
does not affect the HLA-G binding to MEM-G/9. For this
reason we hypothesized that HLA-G immunosuppressive
function was not affected by NO. To address this point
we decided to study the HLA-G inhibitory capability in
different situations: NK cell cytotoxicity, T-cell alloproli-
feration in mixed lymphocyte reaction, and T-cell
response to IL-2 plus anti-CD3. To achieve a maximum
effect of NO in HLA-G modification, we used the highest
concentration previously employed.
Natural killer cells induced the lysis of the M8-pcDNA
melanoma cell line, and preincubation of M8-pcDNA
cells with DETA-NO 1 mM for 24 hr before the cytotoxic
assay did not modify the susceptibility of these cells to
NK cell cytotoxicity (Fig. 6a). As expected,37 M8-HLA-
G1-transfected cells were significantly more resistant to
NK cytotoxicity (P < 005 compared to M8-pcDNA cells).
Preincubation of M8-HLA-G1-transfected cells with
DETA-NO did not abolish the tolerogenic effect of
HLA-G1.
The effect of NO in HLA-G suppressive properties of
T-cell alloproliferation was checked by a MLR using LCL
cells as stimulatory cells and PBMC as responder cells
(Fig. 6b). When HLA-G5 attached to beads through the
anti-HLA-G5 antibodies 5A6G7 or 6A10 was present in
the MLR, there was a clear decrease of lymphocyte allo-
proliferation. To exclude that the effect was the result of
the beads alone, the MLR was also performed in the pres-
ence of beads with the antibody attached. The prolifera-
tion was much lower when the beads had HLA-G5
attached than when the beads had only the antibody
(Fig. 6b). If the HLA-G5-coated beads were previously
treated with DETA-NO for 24 hr and then added to the
MLR, the proliferative levels were not different compared
with those obtained with untreated HLA-G5-beads.
Finally, we studied the proliferation of T cells stimu-
lated with IL-2 plus anti-CD3 in the presence of superna-
tants containing sHLA-G1 treated or not with DETA-NO.
This sHLA-G1-containing supernatant produced a
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Figure 4. Human leucocyte antigen G (HLA-G) expression in JEG-3
cells treated with different concentrations of DETA-NO for 24 hr.
(a) Western blot analysis of HLA-G expression in JEG-3 cells. Bands
of HLA-G1 immunodetection with anti-HLA-G antibody MEM-G/1
appeared at 39 000. Loading control was performed using an anti-
body against b-actin, which produced a band of 42 000. Data indi-
cate the intensity of the HLA-G band related to the b-actin band
and are representative of three different experiments. (b) HLA-G
messenger RNA expression analysed by real-time reverse transcrip-
tion–polymerase chain reaction. Data are shown as relative quantities
of HLA-G transcripts compared to control untreated JEG-3 cells
(assigned a value of 1). Results are expressed as mean ± standard
deviation of three different experiments.
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Figure 3. Effect of SIN-1 in the measurement of shed human leuco-
cyte antigen G (HLA-G1) by enzyme-linked immunosorbent assay
(ELISA). Conditioned medium from U-937-HLA-G1 cells was trea-
ted with different concentrations of SIN-1 for 12 hr, and the concen-
tration of sHLA-G1 was measured by ELISA. Results show relative
quantities of HLA-G concentration compared to control untreated
cells (assigned a value of 100), and are expressed as mean ± standard
deviation of three different experiments. *P < 005 related to control
untreated cells.
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Figure 5. (a) Effect of DETA-NO (left) or SIN-1
(right) on human leucocyte antigen G (HLA-G)
shedding from U-937-HLA-G1 cells. Cells were
treated with different concentrations of nitric
oxide (NO) donor for 24 hr without (dark bars)
or with the NO scavenger haemoglobin 20 lm
(grey bars). Total HLA-G was quantified by
enzyme-linked immunosorbent assay (ELISA).
Results show relative quantities of HLA-G con-
centration compared to control untreated cells
(assigned a value of 100), and are expressed as
mean ± standard deviation of three different
experiments. *P < 005 related to control
untreated cells. (b) Modulation of the effect of
DETA-NO in HLA-G liberation by matrix
metalloproteases. U-937-HLAG1 cells were
untreated or treated with DETA-NO 300 lm for
12 hr without or with the matrix metallopro-
tease inhibitors 50 lm: GM6001, its negative
control, NC-GM6001, INH 2/9, INH 3, INH 8.
Top panel: flow cytometry analysis using MEM-
G/9-FITC. Shaded histograms represent control
cells and open histograms represent cells treated
with DETA-NO. Dotted peaks represent irrele-
vant isotypic antibody. A representative experi-
ment out of three is shown. Bottom panel: shed
HLA-G1 in supernatant quantified by ELISA.
Results show relative quantities of HLA-G con-
centration compared to control untreated cells
(assigned a value of 100), and are expressed as
mean ± standard deviation of three different
experiments. *P < 005 related to control
untreated cells.
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significantly lower proliferation compared to the superna-
tants obtained from the control cells (P < 005; Fig. 6c).
Preincubation of supernatants containing sHLA-G1 with
DETA-NO 1 mM for 24 hr did not affect the proliferation
induced by IL-2 plus anti-CD3.
These results clearly show that NO does not modify the
capability of HLA-G in relation to the inhibition of NK
and T-cell response.
Discussion
We have found that HLA-G protein can be nitrated and,
to our knowledge, this is the first report of a post-transla-
tional modification of HLA-G protein. However, not all
the HLA-G is nitrated, which means that there is some
type of hindrance to this reaction,4 or that only some of
the HLA-G molecules have a configuration prone to
nitration. Nitration depends on different factors, such as
the protein concentration, the proximity to the site of
generation of nitrating agents, and the tyrosine environ-
ment.4 The higher degree of nitration associated with a
lower capacity of HLA-G detection by our ELISA method
suggest that nitration affects the properly folded HLA-G
plus b2-microglobulin complex.
36 However, noticeable
interference by NO in HLA-G measurement using MEM-
G/9 plus anti-b2-microglobulin antibodies should not be
initially expected under physiological NO production.
Nitration can also be produced by endogenous NO, as
occurs in the case of U-937-HLA-G1 and M8-HLAG5
cells, where NO production by iNOS nitrates HLA-G in
baseline conditions. The intracellular production of NO
and the cellular oxidative metabolism lead to intracellular
protein modifications.38 The modified HLA-G can also be
found in the medium, suggesting that detection of
nitrated HLA-G in biological fluids could be a hallmark
of HLA-G production at the inflammatory site.4
We showed in this work that NO decreases HLA-G cell
surface levels by HLA-G shedding through a matrix
metalloprotease-dependent mechanism, as the inhibitor
GM6001 blocked NO-induced HLA-G1 shedding. Previ-
ous studies have shown that metalloproteases are involved
in HLA-G1 shedding,20,21 and NO can induce the activity
and expression of matrix metalloproteases in different cell
models, such as macrophages39 and trophoblasts.40 There
are different metalloproteases that differ in their substrate
specificity,41 and the proteolytic shedding of HLA-G is
not common to all matrix metalloproteases, as the inhibi-
tor of matrix metalloproteases 2 and 9 had no effect on
HLA-G shedding.
Generation of free radicals and oxidants, like reactive
oxygen or nitrogen species, is a common result of metabo-
lism and pathological processes.1 Concentration of NO
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Figure 6. (a) Effect of DETA-NO on the human leucocyte antigen G
(HLA-G)-mediated inhibition of cytotoxicity. Data show the percent-
age of specific lysis achieved by NKL cells in 4 hr of coculture, with
M8-pcDNA or M8-HLA-G1 cells as target cells. Target cells were
previously incubated without (white bars) or with DETA-NO 1 mm
(grey bars) for 24 hr. Results are expressed as mean ± standard devi-
ation of three different experiments. *P < 005 related to control
untreated cells. (b) Effect of DETA-NO on the HLA-G-mediated
inhibition of mixed lymphocyte reaction. The proliferation of
peripheral blood mononuclear cells was measured by [3H]thymidine
incorporation in a mixed lymphocyte reaction with LCL cells as
stimulatory cells. Beads with HLA-G5 attached were added untreated
(shaded bars) or treated with DETA-NO 1 mm for 24 hr (dark bars).
Beads with only the corresponding linking antibody (5A6G7 or
6A10) were added as controls (open bars). Results are expressed as
mean ± standard deviation of a triplicate experiment. (c) Effect of
DETA-NO on the HLA-G-mediated inhibition of T-cell prolifera-
tion. The proliferation of T lymphocytes after stimulation with inter-
leukin-2 (2000 U/ml) and anti-CD3 (025 lg/ml) was measured
through bromodeoxyuridine incorporation. T lymphocytes were
preincubated for 5 hr with culture supernatant from U-937 cells or
from U-937-HLA-G1 cells (open bars), or with these supernatants
pre-treated with DETA-NO 1 mm for 24 hr (shaded bars). Results
are expressed as mean ± standard deviation of three different experi-
ments. *P < 005 related to control untreated cells.
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in vivo at the site of inflammation is usually in the micro-
molar range42 so, increased levels of circulating HLA-G in
some inflammatory diseases24,25 could reflect both an
increased HLA-G expression and NO-induced shedding
from the cell membrane. NO-dependent HLA-G modula-
tion can be responsible in some circumstances for the nega-
tive HLA-G expression at the cell surface, while protein
expression is observed inside the cell and in the medium.43
In preeclampsia there is peroxynitrite production,44 and
lower HLA-G expression in trophoblasts.45,46 We have also
observed in JEG-3 cells that NO decreases HLA-G cell sur-
face expression and increases shedding (data not shown).
These findings could be linked in the light of these results;
i.e. NO could participate in HLA-G down-regulation and
nitration in this disease.
Importantly, the presence of NO did not affect the HLA-
G immune suppressive properties, as HLA-G maintained
the capability to inhibit NK cytotoxicity and lymphocyte
proliferation. It was conceivable that the remaining non-
nitrated HLA-G accounted for these inhibitory properties,
as we have shown previously that, even in these pro-oxi-
dant conditions, it is not completely nitrated and exists
predominantly in its native form. We ruled out the effect of
re-expression of un-nitrated HLA-G because in the prolif-
eration assays we used soluble HLA-G pretreated with NO
donor, which was still suppressive. NO can inactivate other
suppressive molecules such as IDO,31 and the fact that
HLA-G is protective under this type of oxidative stress rein-
forces the notion of a relevant, and not redundant, tolero-
genic role of HLA-G in pregnancy or in tumour immune
evasion.13,47 NO-promoted HLA-G shedding can be a
mechanism to extend immunoregulation to the surround-
ing tissue under stressful conditions, as it could occur in
placenta, where both HLA-G10 and NOS are coexpressed.23
HLA-G trogocytosis48 was recently postulated as another
mechanism used by tissues to spread immune protection
based on intermembrane HLA-G transfer.
In summary, in this work we have demonstrated that
NO nitrates HLA-G protein, and decreases HLA-G cell
surface expression by increasing metalloprotease-depen-
dent shedding. However, HLA-G keeps its suppressive
properties, which could maintain immune protection
under oxidative stress, such as that created by oxygen free
radicals and NO, while other tolerogenic molecules are
inactivated by these agents.
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